Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma

CAR-T Digest - August 2020

23 May 2025: Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma

CHMP of EMA recommended approval of Blenrep for relapsed/refractory multiple myeloma in combinations BVd (for patients with ≥1 prior therapy) and BPd (for those previously treated with lenalidomide)
The decision is based on positive results from DREAMM-7 and DREAMM-8 trials showing superior progression-free survival (PFS) and overall survival (OS) compared to standard treatments
Approval already granted by UK MHRA and Japan’s Ministry of Health; European Commission decision expected Q3 2025
Blenrep, the only anti-BCMA antibody-drug conjugate, offers in-office administration and manageable side effects, including reversible eye-related issues
DREAMM-7 showed median PFS of 36.6 vs 13.4 months and 42% reduced death risk versus daratumumab-based combo; DREAMM-8 showed significant PFS benefit and OS trend favoring Blenrep